Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
Carol A BurkeEvelien DekkerPatrick LynchN Jewel SamadderFrancesc BalaguerRobert HüneburgJohn BurnAntoni CastellsSteven GallingerRamona LimElena M StoffelSamir GuptaAlex HendersonFrank G KallenbergPriyanka KanthVictorine H RoosGregory G GinsbergFrank A SinicropeChristian P StrassburgEric Van CutsemJames ChurchFiona LallooField F WillinghamPaul E WiseWilliam M GradyMolly FordJennifer M WeissRobert GryfeAnil K RustgiSapna SyngalAlfred CohenPublished in: The New England journal of medicine (2020)
In this trial involving patients with familial adenomatous polyposis, the incidence of disease progression was not significantly lower with the combination of eflornithine and sulindac than with either drug alone. (Funded by Cancer Prevention Pharmaceuticals; ClinicalTrials.gov number, NCT01483144; EudraCT number, 2012-000427-41.).